Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.50 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.46 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12052082 | 1.00 | PARP10 (0.53) | PARP10ROCK2ROCK1PARP4PARP1 | |
| SCHEMBL8254658 | 1.00 | PARP10 (0.53) | PARP10ROCK2ROCK1PARP4PARP1 | |
| SCHEMBL84429 | 0.84 | HTT (0.61) | PARP10PARP4PARP1CA2CA1 | |
| SCHEMBL28953743 | 0.84 | ROCK2 (0.51) | ROCK2ROCK1ADRB2ALDH1A1KMT2A | |
| Water SCHEMBL4672025 | 0.82 | HTT (0.59) | PARP10PARP4PARP1CA2CA1 | |
| SCHEMBL2422833 | 0.82 | PARP10 (0.53) | PARP10PARP4PARP1CA2CA1 | |
| SCHEMBL4878931 | 0.82 | ANPEP (0.57) | ROCK2ROCK1CA2CA1ADRB2 | |
| SCHEMBL12600654 | 0.82 | PARP10 (0.53) | PARP10PARP4PARP1CA2CA1 | |
| Hydrochloric Acid SCHEMBL4372836 | 0.82 | HTT (0.59) | PARP10PARP4PARP1CA2CA1 | |
| Terephthalic Acid SCHEMBL8743590 | 0.82 | ANPEP (0.57) | ROCK2ROCK1CA2CA1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-12-01 | — | — | US | disclosed |
| CN-114555573-A | Prostaglandin E2(PGE2)EP4Receptor antagonists | 多曼治疗学公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| CN-100411686-C | Agent for improving visual function disorder | SENJU PHARMA CO (JP) | 2008-08-20 | — | — | CN | disclosed |
| CN-1323719-C | Remedy for glaucoma comprising Rho kinase inhibitor and beta-blocker | SANTEN PHARMACEUTICAL CO LTD (JP) | 2007-07-04 | — | — | CN | disclosed |
| WO-2006116157-A9 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS INC (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006116157-A2 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| CN-1711107-A | Remedy for glaucoma comprising Rho kinase inhibitor and beta-blocker | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-12-21 | — | — | CN | disclosed |
| CN-1684689-A | Glaucoma-treating agent consisting of RHo kinase inhibitor and prostaglandin | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-10-19 | — | — | CN | disclosed |
| CN-1501813-A | Agent for improving visual function disorder | 千寿制药株式会社 | 2004-06-02 | — | — | CN | disclosed |
| US-4894387-A | RELIEF FROM PAIN FROM VASODILATION | GLAXO GROUP LIMITED (GB) | 1990-01-16 | — | — | US | disclosed |
| EP-0147107-B1 | INDOLE DERIVATES | GLAXO GROUP LIMITED (GB) | 1989-08-02 | — | — | EP | disclosed |
| EP-0147107-A1 | Indole derivates | GLAXO GROUP LIMITED (GB) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | PARP10 1019/4885ROCK2 1632/4885ROCK1 1446/4885 |
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | VNN1, VAT1, CMA1 | PARP10 1790/4885ROCK2 4847/4885ROCK1 4714/4885 |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | VNN1, MVD, VAT1 | PARP10 2359/4885ROCK2 4870/4885ROCK1 4804/4885 |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER2 | PARP10 891/4885ROCK2 1222/4885ROCK1 1245/4885 |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | VNN1, CMA1, VAT1 | PARP10 2356/4885ROCK2 4858/4885ROCK1 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.